deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01207687

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma

Sponsor: National Cancer Institute (NCI)

Conditions Neurofibromatosis Type 2 Vestibular Schwannoma
Interventions bevacizumab laboratory biomarker analysis quality-of-life assessment
Updated 9 times since 2017 Last updated: Jul 27, 2018 Started: Oct 31, 2010 Primary completion: Feb 28, 2013 Completion: Mar 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neurofibromatosis Type 2 and Vestibular Schwannoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotCompleted~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotCompleted~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotCompleted~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshotCompleted~Sep 2018 – ~Jan 2021 · 28 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Sep 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Aug 2018 — Sep 2018 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Completed PHASE2

  2. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Feb 2017 — Sep 2017 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations